<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The principal pathophysiological mechanism in patients with unstable <z:hpo ids='HP_0001681'>angina pectoris</z:hpo> (UAP) and non-Q-wave <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (NQMI) is atherothrombosis--the formation of a platelet-rich <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> at the site of a disrupted or eroded atherosclerotic plaque </plain></SENT>
<SENT sid="1" pm="."><plain>Despite standard therapy, which includes intravenous <z:chebi fb="5" ids="28304">heparin</z:chebi> or low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> and <z:chebi fb="0" ids="15365">acetylsalicylic acid</z:chebi> (<z:chebi fb="37" ids="15365">ASA</z:chebi>) during the <z:hpo ids='HP_0011009'>acute</z:hpo> phase followed by <z:chebi fb="37" ids="15365">ASA</z:chebi> on a long-term basis, the prognosis for patients remains poor </plain></SENT>
<SENT sid="2" pm="."><plain>The efficacy of early and long-term treatment with <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> (<z:chebi fb="0" ids="37941">clopidogrel</z:chebi> bisulphate) on top of standard therapy including <z:chebi fb="37" ids="15365">ASA</z:chebi> has recently been tested in patients with UAP and NQMI </plain></SENT>
<SENT sid="3" pm="."><plain>In the CURE (<z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> in Unstable <z:mp ids='MP_0006112'>Angina</z:mp> to Prevent Recurrent Ischaemic Events) Trial, more than 12,500 patients were randomized, in a double-blind manner, to receive placebo or <z:chebi fb="0" ids="37941">clopidogrel</z:chebi>, given as an initial 300-mg loading dose, followed by a 75-mg daily dose </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received a recommended dose of <z:chebi fb="37" ids="15365">ASA</z:chebi> (75-325 mg daily) </plain></SENT>
<SENT sid="5" pm="."><plain>The mean duration of treatment and follow-up was 9 months (minimum 3 months, maximum 12 months) </plain></SENT>
<SENT sid="6" pm="."><plain>CURE clearly showed that <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> reduced the risk of a composite of cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo> and MI, with a relative risk reduction of 20% (95% confidence interval, 72-90%; p &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>The protective effect of <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> was apparent within 2 h of initiation of therapy, and the benefit was consistent at 30 days and after long-term treatment </plain></SENT>
<SENT sid="8" pm="."><plain>The benefit of <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> was observed across the spectrum of high- and low-risk patients and was obtained with an acceptable risk of <z:mp ids='MP_0001914'>bleeding</z:mp> and no increase in intracranial haemorrhage </plain></SENT>
<SENT sid="9" pm="."><plain>Based on data from CURE, the use of <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> on top of standard therapy including <z:chebi fb="37" ids="15365">ASA</z:chebi> can be expected to become the new foundation therapy in patients with UAP and NQMI </plain></SENT>
</text></document>